Price
$3.83
Decreased by -0.78%
Dollar volume (20D)
5.79 M
ADR%
6.71
Earnings report date
Jun 28, 2024
Shares float
131.69 M
Shares short
3.59 M [2.73%]
Shares outstanding
266.04 M
Market cap
1.03 B
Beta
2.02
Price/earnings
N/A
20D range
3.78 4.78
50D range
3.61 5.41
200D range
2.01 7.45

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.

The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.

Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Mar 14, 24 -0.45
Decreased by -95.65%
-0.25
Decreased by -80.00%
Nov 2, 23 -0.26
Increased by +44.68%
-0.25
Decreased by -4.00%
Aug 3, 23 -0.26
Increased by +43.48%
-0.22
Decreased by -18.18%
May 4, 23 -0.23
Increased by +43.90%
-0.27
Increased by +14.81%
Mar 7, 23 -0.23
Increased by +54.90%
-0.27
Increased by +14.81%
Nov 3, 22 -0.47
Increased by 0.00%
-0.46
Decreased by -2.17%
Aug 4, 22 -0.46
Increased by +2.13%
-0.42
Decreased by -9.52%
May 5, 22 -0.41
Increased by +21.15%
-0.48
Increased by +14.58%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 1.77 M
Decreased by -53.59%
-77.17 M
Decreased by -186.34%
Decreased by -4.35 K%
Decreased by -517.04%
Sep 30, 23 406.00 K
Decreased by -82.86%
-45.85 M
Decreased by -7.21%
Decreased by -11.29 K%
Decreased by -525.55%
Jun 30, 23 0.00
Decreased by N/A%
-45.55 M
Decreased by -8.31%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 1.29 M
Increased by +N/A%
-39.81 M
Decreased by -7.42%
Decreased by -3.08 K%
Decreased by N/A%
Dec 31, 22 3.83 M
Increased by +364.76%
-26.95 M
Increased by +35.32%
Decreased by -704.60%
Increased by +86.08%
Sep 30, 22 2.37 M
Increased by +N/A%
-42.77 M
Decreased by -25.82%
Decreased by -1.81 K%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
-42.06 M
Decreased by -26.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-37.06 M
Decreased by -11.41%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY